Revance Therapeutics

Revance Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development, manufacturing, and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic applications. The firm focuses on production of daxibotulinumtoxinA, a botulinum toxin, for aesthetic and therapeutic indications including facial wrinkles and muscle movement disorders. The company was founded by Jacob M. Waugh and L. Daniel Browne on August 10, 1999 and is headquartered in Nashville, TN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revance Therapeutics excels in Q4 with DAXXIFY approval driving growth

Revance Therapeutics demonstrated strong financial performance and strategic focus in Q4 2022, driven by DAXXIFY sales and revenue growth.
The company's strengths lie in DAXXIFY approval, positive market feedback, and partnerships positioning them well for future growth.
Challenges include competitive dynamics, pricing strategies, and managing increased OpEx, while opportunities exist in market expansion and new product programs.
Overall, Revance is optimistic about their market position and future prospects, emphasizing customer relationships and strategic investments.

Revance Therapeutics posts stellar Q1 results, eyes market expansion

Revance Therapeutics delivered strong Q1 results, driven by robust RHA Collection and DAXXIFY sales, positioning the company for future growth.
While facing challenges in undisclosed market data and paused clinical trials, Revance's strategic focus on market entry and product adoption presents opportunities for expansion.
With a solid cash position, upcoming milestones, and market potential, Revance is poised for continued success in the neuromodulator and therapeutics segments.

Revance Therapeutics reports record revenue growth and strategic expansion

Revance Therapeutics had a robust Q2 2023, marked by strong revenue growth, expanded sales force, and successful marketing efforts.
While facing challenges in market reception and adoption rates for DAXXIFY, the company remains optimistic about driving growth and leveraging opportunities.
With a focus on sales force expansion, product education, and strategic initiatives, Revance is poised for continued commercial progress and success.

Revance Therapeutics reports strong Q3 growth driven by DAXXIFY

Revance Therapeutics is strategically focusing on DAXXIFY launch success, aesthetics growth, and therapeutics opportunities. Despite challenges in account responses and revenue guidance uncertainties, the company remains optimistic about expanding DAXXIFY adoption and maintaining a strong financial position.

Revance Therapeutics reports record revenue, eyes growth in 2024

Revance Therapeutics had a strong performance in 2023, focusing on growth and cost controls for future success.
The company's strategic initiatives and product offerings position it well for continued growth and market expansion.
Challenges in managing expenses and achieving profitability are being addressed with targeted strategies.
Optimism surrounds the potential of DAXXIFY and the company's ability to capitalize on market opportunities.

Revance Therapeutics (RVNC) reports strong Q1 performance and strategic market entry

Revance Therapeutics (RVNC) demonstrated strong performance in Q1 2024, driven by growth in DAXXIFY and RHA filler market share, with a strategic entry into the therapeutic neurotoxin market.
The company's focus on innovation, efficiency, and market expansion presents opportunities for revenue growth and competitive positioning, despite challenges in differentiation and market dynamics.
Efforts to drive product adoption, enhance customer engagement, and optimize operational efficiency underscore Revance's commitment to sustainable financial health and long-term success.
Overall, Revance's Q1 performance reflects positive momentum and strategic initiatives aimed at capitalizing on market opportunities and strengthening its competitive position.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance Announces Proposed Public Offering of Common Stock.

Revance Announces Proposed Public Offering of Common Stock

Revance Therapeutics Inc. (RVNC) Q4 2023 Earnings Call Transcript

NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance Reports Fourth Quarter and Full Year 2023 Financial Results, Provides Corporate Update.

Revance Reports Fourth Quarter and Full Year 2023 Financial Results, Provides Corporate Update

NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance to Release Fourth Quarter and Full Year 2023 Financial Results on Wednesday February 28, 2024.

Revance to Release Fourth Quarter and Full Year 2023 Financial Results on Wednesday February 28, 2024

NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance Receives Permanent J-Code for DAXXIFY® and Announces Publication of DAXXIFY Pivotal Study (ASPEN-1) Results in Neurology®.

Revance Receives Permanent J-Code for DAXXIFY® and Announces Publication of DAXXIFY Pivotal Study (ASPEN-1) Results in Neurology®

NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance to Participate in the Guggenheim 6th Annual Biotechnology Conference.

Revance to Participate in the Guggenheim 6th Annual Biotechnology Conference

NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance Provides Corporate Update, Preliminary Fourth Quarter and Full Year 2023 Financial Results, and Financial Outlook.

Revance Provides Corporate Update, Preliminary Fourth Quarter and Full Year 2023 Financial Results, and Financial Outlook

Revance Therapeutics, Inc. (NASDAQ:RVNC ) Q3 2023 Earnings Conference Call November 8, 2023 4:30 PM ET Company Participants Jessica Serra - Head, IR, Communications & ESG Mark Foley - CEO Dustin Sjuts - President Toby Schilke - CFO Conference Call Participants Seamus Fernandez - Guggenheim Partners Mikaela Franceschina - Barclays David Amsellem - Piper Sandler Stacy KU - TD Cowen Annabel Samimy - Stifel Uy Ear - Mizuho Serge Belanger - Needham and Company Douglas Tsao - H.C. Wainwright Terence Flynn - Morgan Stanley Navann Ty - BNP Paribas Operator Welcome to the Revance Therapeutics Third Quarter 2023 Financial Results and Corporate Update Conference Call.

Revance Therapeutics, Inc. (RVNC) Q3 2023 Earnings Call Transcript

Although the revenue and EPS for Revance Therapeutics, Inc. (RVNC) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Revance Therapeutics, Inc. (RVNC) Reports Q3 Earnings: What Key Metrics Have to Say

NASHVILLE--(BUSINESS WIRE)--Revance Reports Third Quarter 2023 Financial Results, Provides Corporate Update.

Revance Reports Third Quarter 2023 Financial Results, Provides Corporate Update

NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance Appoints Erica Jordan as Chief Commercial Officer, Aesthetics.

Revance Appoints Erica Jordan as Chief Commercial Officer, Aesthetics

NEW YORK , Nov. 3, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Revance Therapeutics, Inc. ("Revance" or the "Company") (NASDAQ: RVNC). Such investors are advised to contact Robert S.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Revance Therapeutics, Inc. - RVNC

NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance to Release Third Quarter 2023 Financial Results on Wednesday, November 8, 2023.

Revance to Release Third Quarter 2023 Financial Results on Wednesday, November 8, 2023

NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance Provides Corporate Update at Investor Day.

Revance Provides Corporate Update at Investor Day

Revance Therapeutics, Inc. stock has fallen by half in the past six months, despite impressive sales growth, prompting speculation on whether it is now a good buy. The recent DAXXIFY launch seems to be proceeding well, but quarterly cash burn remains an issue as Revance challenges Botox in this space. Analysts have mixed opinions on the stock, with some reiterating buy ratings and others issuing neutral ratings.

Revance Therapeutics: Impressive Sales Growth/Concerning Cash Burn

Novocure

SAGE Therapeutics

The healthcare industry comprises multiple sectors, including biotechnology, pharmaceuticals, and healthcare equipment, each offering a unique and potentially risky opportunity. News regarding FDA approval and positive results for therapies, pharmaceuticals, and trials greatly influences the outlook for companies, especially ones with small market cap share price.

3 Healthcare Stocks to Sell in September Before They Crash & Burn

ImmunityBio

TG Therapeutics

After I spent many years following Wall Street, there are a few characteristics about the “big money”  that stand out for me. One of these traits is that many if not most large investors are very reluctant to buy stocks that have a 60%-80% chance of climbing a great deal in the long term but a 10%-15% chance of plunging in the short-to-medium term.

3 Very Oversold Biotech Stocks to Buy Right Now

Apellis Pharma

In the financial markets, not everything always goes up, not everything always goes down. The fluctuations in the share prices of listed companies are constant.

3 Very Oversold Pharma Stocks to Buy Right Now

NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance to Host Investor Day on September 19, 2023.

Revance to Host Investor Day on September 19, 2023

Revance's frown-line injection, Daxxify, gained U.S. approval on Monday to treat an involuntary movement disorder, and RVNC stock rose.

How Revance Is Taking A Page Out Of AbbVie's Botox Playbook

Shares of Revance Therapeutics Inc. RVNC, -3.81% gained 8% premarket on Monday after the U.S. Food and Drug Administration approved the biotech company's Daxxify injection for treatment of cervical dystonia in adults. Cervical dystonia is a chronic disease that causes painful, involuntary neck muscle contractions and affects about 60,000 people in the U.S. Daxxify, a Botox competitor, previously received FDA approval late last year for the temporary improvement of frown lines.

Revance shares gain 8% after FDA approval of cervical dystonia treatment

The U.S. health regulator has approved expanding the use of Revance Therapeutics' Daxxify to treat a painful neck muscle condition, intensifying the anti-wrinkle injection's rivalry with AbbVie's Botox.

Revance's Botox rival gets FDA approval for painful neck muscle condition

NASHVILLE, Tenn.--(BUSINESS WIRE)--U.S. FDA Approves First Therapeutic Indication for Revance's DAXXIFY® (DaxibotulinumtoxinA-lanm) for Injection for the Treatment of Cervical Dystonia.

U.S. FDA Approves First Therapeutic Indication for Revance's DAXXIFY® (DaxibotulinumtoxinA-lanm) for Injection for the Treatment of Cervical Dystonia

Revance Therapeutics, Inc. (NASDAQ:RVNC ) Q2 2023 Earnings Conference Call August 8, 2023 4:30 PM ET Company Participants Jessica Serra - Head, IR & ESG Mark Foley - CEO & Director Dustin Sjuts - President Tobin Schilke - CFO & Principal Accounting Officer Conference Call Participants Seamus Fernandez - Guggenheim Securities David Amsellem - Piper Sandler & Co. Chris Shibutani - Goldman Sachs Group Stacy Ku - TD Cowen Timothy Lugo - William Blair & Company Balaji Prasad - Barclays Bank Annabel Samimy - Stifel, Nicolaus & Company Navann Dietschi - BNP Paribas Exane Douglas Tsao - H.C. Wainwright & Co. Terence Flynn - Morgan Stanley Charles Uy - Mizuho Operator Welcome to the Revance Therapeutics Second Quarter 2023 Financial Results and Corporate Update Conference Call.

Revance Therapeutics, Inc. (RVNC) Q2 2023 Earnings Call Transcript

Revance Therapeutics, Inc. (RVNC) came out with a quarterly loss of $0.80 per share versus the Zacks Consensus Estimate of a loss of $0.72. This compares to loss of $0.88 per share a year ago.

News for Revance Therapeutics Stock (RVNC)